文献速递糖尿病骨质疏松与钙磷/甲状旁腺

GLP-1受体激动剂与老年2型糖尿病患者脆性骨折风险

GLP-1 receptor agonists and the risk of fragility fractures in older adults with type 2 diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

中位随访34.7个月,经倾向评分加权并考虑死亡竞争风险后,GLP-1RA组脆性骨折风险较对照组增加11%(HR 1.11;95%CI 1.01-1.21)。

要点

  • 老年2型糖尿病患者启动GLP-1RA治疗与脆性骨折风险轻度增加相关(HR 1.11)。
  • 该关联来自倾向评分加权并考虑死亡竞争风险的生存分析。
  • 临床决策需在代谢与心血管获益和潜在骨骼风险间权衡。

核心结论

  • 在老年2型糖尿病患者中,启动GLP-1RA治疗与脆性骨折风险轻度增加相关。

研究设计与样本

  • 基于全国性Clalit Health Services数据库的回顾性新用户队列研究。
  • 纳入2018至2022年间启动GLP-1RA或对照药(SGLT-2i或DPP-4i)的65岁及以上2型糖尿病患者。
  • 采用意向性治疗分析,以倾向评分逆概率治疗加权平衡基线特征,并采用多变量生存分析考虑死亡竞争风险。

主要发现

  • 中位随访34.7个月期间,4086例(8.8%)发生脆性骨折,4595例(10.0%)死亡。
  • 在倾向评分加权并调整基线特征及死亡竞争风险的模型中,GLP-1RA新使用者较对照组脆性骨折风险增加11%(HR 1.11;95%CI 1.01-1.21)。

临床怎么用

  • 对于老年2型糖尿病患者,处方GLP-1RA时应综合评估骨折风险,权衡其代谢与心血管获益及潜在骨骼风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are increasingly prescribed to older adults with type 2 diabetes for their metabolic and cardiovascular benefits, but their effects on bone health in this high-risk population are not well established. OBJECTIVE: The aim of this study was to assess the risk of fragility fractures associated with GLP-1RA therapy compared to sodium-glucose cotransporter-2 inhibitors or dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes. METHODS: We conducted a population-based retrospective new-user cohort study using the nationwide Clalit Health Services database. Participants included people with type 2 diabetes aged 65 years or older who initiated GLP-1RA therapy or comparator drugs during 2018 to 2022. The primary outcome was first fragility fracture. Follow-up continued until fracture occurrence, death, or March 31, 2024. An intention-to-treat approach was used. Baseline characteristics were balanced using inverse probability of treatment weighting based on propensity scores. Hazard ratios (HRs) were estimated using multivariate survival analysis accounting for the competing risk of death. RESULTS: The study included 46 177 participants: 11 257 GLP-1RA users and 34 920 comparator drug users. During a median follow-up of 34.7 months, 4086 (8.8%) individuals experienced a fragility fracture and 4595 (10.0%) died. In the propensity score-weighted model adjusted for baseline characteristics and competing risk of death, new users of GLP-1RAs had an 11% increased fracture risk compared to the comparator group (HR 1.11; 95% CI, 1.01-1.21). CONCLUSION: Initiating GLP-1RA therapy was associated with a modestly increased risk of fragility fractures in older adults with type 2 diabetes. These findings may inform clinical decisions by balancing clinical benefits against potential skeletal risks in this vulnerable population.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Kasher Meron M, Hornik-Lurie T, Twig G, et al. GLP-1 receptor agonists and the risk of fragility fractures in older adults with type 2 diabetes. J Clin Endocrinol Metab. 2026. PMID: 41665888. doi:10.1210/clinem/dgag056

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。